University Of Pecs
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment
At the University Of Pecs, clinical research in diagnostic imaging focuses on improving magnetic resonance imaging for patients with suspected non-central nervous system conditions. The work is centered on evaluating whether a newer contrast agent can provide reliable imaging performance compared with established options.
- Assessment of MRI contrast enhancement for better visualization of non-central nervous system pathology
- Testing the effectiveness of a new contrast agent against commonly used alternatives
- Supporting safer and more accurate diagnostic imaging in routine clinical practice
This research area reflects a strong interest in refining imaging tools that help clinicians identify disease more clearly and efficiently.
Diseases of the Ear, Nose, and Throat
The Fül-Orr-Gégészeti és Fej-Nyaksebészeti Klinika is actively involved in studies on chronic rhinosinusitis in adults, especially in people without nasal polyps who have not improved with standard medical care. These trials are designed to evaluate whether a new local therapy can ease the main symptoms of the condition.
- Research on chronic rhinosinusitis in adults without nasal polyps
- Evaluation of symptom relief for persistent sinus disease
- Comparing a new treatment approach with a sham control to measure clinical benefit
The focus is on improving treatment options for patients with long-lasting sinus inflammation and related quality-of-life concerns.
Diseases of the Urinary System and Neoplasms
Another key research area at this site involves high risk non-muscle invasive bladder cancer, where investigators are studying whether adding an immunotherapy to standard BCG treatment can improve outcomes. The goal is to better control disease recurrence and extend the time patients remain free from progression.
- Studies in high risk bladder cancer with non-muscle invasive disease
- Evaluation of immunotherapy combined with standard bladder cancer treatment
- Measuring treatment effectiveness in reducing recurrence and improving disease control
These trials highlight a broader effort to strengthen cancer care through more effective combination treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Pecs
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 1 | Unknown | 2023-06-05 | 2023-06-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.